Osteoporosis, bone & mineral

Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea

J Bone Miner ResPublished Retrospective cohort study

Main finding · Total fractureResult — go to the resultHazard ratio 1.06 95% CI 0.98–1.15

Authors' conclusion

In real-world data reflecting clinical practice, denosumab and bisphosphonate showed comparable effectiveness for total fractures and major osteoporosis fractures, as well as safety regarding acute kidney injury, chronic kidney disease, and atypical femoral fracture.

Study context

Population
Subjects over 50 yr taking denosumab or bisphosphonate, January 2018 to April 2022, Health Insurance Review and Assessment Service database (20% sample of Korean population), South Koreapropensity score matched
Participants
91,460 participants
Exposure
Denosumab vs bisphosphonate
Outcome
Treatment effectiveness (total, major osteoporotic, femur, pelvic and vertebral fracture) and adverse drug reactions (acute kidney injury, CKD, atypical femoral fracture)
Methodological detailsnationwide claims database, 1:1 propensity score matching
  • Nationwide claims database
  • 1:1 propensity score matching

Main finding

Total fracture

Hazard ratio

1.06

95% CI 0.98–1.15

P = 0.14

Denosumabvs Bisphosphonate
HR 1.06 (95% CI 0.98–1.15); P = 0.14

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeHR (95% CI)P value
Major osteoporotic fractureComparable1.13 (0.97–1.32)P = 0.12

Safety

OutcomeHR (95% CI)P value
Acute kidney injury, age <70 yr subgroupSignificantly lower risk with denosumab · subgroup analysis by age0.53 (0.29–0.93)P = 0.03

Acute kidney injury, CKD and atypical femoral fracture

No differences between the 2 groups

Original publication

Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea. J Bone Miner Res. Published 9 May 2024. doi:10.1093/jbmr/zjae070

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.